89biologo.png
89bio to Present at the SVB Leerink 10ᵗʰ Annual Global Healthcare Conference
February 18, 2021 08:00 ET | 89bio, Inc.
SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Provides Business Outlook for 2021
January 05, 2021 08:00 ET | 89bio, Inc.
-Phase 2b NASH trial as part of a potential Phase 2b/3 program expected to initiate in 1H21- -Topline data from recently initiated NASH paired-biopsy, open-label histology cohort expected by YE21- ...
89biologo.png
89bio to Participate in the H.C. Wainwright BioConnect 2021 Conference
January 04, 2021 08:00 ET | 89bio, Inc.
SAN FRANCISCO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio To Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 24, 2020 08:00 ET | 89bio, Inc.
SAN FRANCISCO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at AASLD’s The Liver Meeting® 2020
November 13, 2020 08:00 ET | 89bio, Inc.
– Data demonstrated compelling efficacy profile and favorable tolerability with weekly and every two-week dosing – – Consistent results and baseline characteristics across biopsy confirmed and...
89biologo.png
89bio Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 10, 2020 16:02 ET | 89bio, Inc.
– Updated clinical data from BIO89-100’s Phase 1b/2a NASH trial to be presented as a late-breaking poster at upcoming AASLD Liver Meeting – – Planning to initiate the Phase 2b trial as part of the...
89biologo.png
89bio To Present Data From Phase 1b/2a Study of BIO89-100 In NASH at AASLD’s The Liver Meeting® 2020
November 02, 2020 08:00 ET | 89bio, Inc.
SAN FRANCISCO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio to Present at Upcoming Investor Conference
September 28, 2020 17:18 ET | 89bio, Inc.
SAN FRANCISCO, Sept. 28, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Announces Pricing of Upsized Public Offering of Common Stock
September 16, 2020 20:51 ET | 89bio, Inc.
SAN FRANCISCO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Announces Proposed Public Offering of Common Stock
September 14, 2020 17:21 ET | 89bio, Inc.
SAN FRANCISCO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...